{
    "address": "Scheelevagen 2 Byggnad 401",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W0470R106",
    "description": "Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody- based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 44 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.",
    "employeeTotal": "44.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2016-11-23",
    "isin": "SE0000767188",
    "logo": "https://finnhub.io/api/logo?symbol=ATORX.ST",
    "marketCapitalization": 533.7013,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Alligator Bioscience AB",
    "phone": "46462864280.0",
    "sedol": "B03HFD5",
    "shareOutstanding": 85.666338,
    "state": "SKANE",
    "ticker": "ATORX.ST",
    "weburl": "https://alligatorbioscience.se/"
}